Management of mantle cell lymphoma in the elderly patient

Jeanette K Doorduijn,1 Hanneke C Kluin-Nelemans2 1Department of Hematology, Erasmus MC, Rotterdam, The Netherlands; 2Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Abstract: Mantle cell lymphoma is a relatively rare B-cell lymphoma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Doorduijn JK, Kluin-Nelemans HC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	treatment progression-free survival chemotherapy malignant lymphoma MLC Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/696b190221214942a998d12a967316cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:696b190221214942a998d12a967316cc
record_format	dspace
spelling	oai:doaj.org-article:696b190221214942a998d12a967316cc2021-12-02T05:00:04ZManagement of mantle cell lymphoma in the elderly patient1178-1998https://doaj.org/article/696b190221214942a998d12a967316cc2013-09-01T00:00:00Zhttps://www.dovepress.com/management-of-mantle-cell-lymphoma-in-the-elderly-patient-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Jeanette K Doorduijn,1 Hanneke C Kluin-Nelemans2 1Department of Hematology, Erasmus MC, Rotterdam, The Netherlands; 2Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Abstract: Mantle cell lymphoma is a relatively rare B-cell lymphoma with a specific genetic lesion and a typical immunophenotypic profile. The median age is 65 years. There is no curative treatment, except allogeneic stem cell transplantation for a selected group of patients. For the majority of patients, especially the elderly, the aim of therapy should therefore be a long progression-free survival. Age and comorbidity may hamper the use of the most active treatment regimen, such as high dose cytarabine and autologous stem cell transplantation. Therefore, it is a challenge to select the most appropriate therapy for an elderly patient. Studies specifically designed for elderly patients are rare. A recently performed large randomized study for elderly patients, however, has shown that R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by maintenance rituximab can result in a long progression-free survival. For patients too frail for R-CHOP chemotherapy, a treatment should be offered that benefits the patient in reducing the symptoms of the disease without causing too many side effects. Progression or relapse will occur in all patients sooner or later. Second-line treatment should again be carefully selected. Several options are mentioned. New drugs are being developed, and new combinations are investigated. Further improvement in the outcome of patients with mantle cell lymphoma is expected. Participation in well-designed clinical trials, also by elderly patients, is important to find the real benefit that can be achieved, and to get information on the tolerability of these treatments in this age group. Keywords: treatment, chemotherapy, malignant lymphoma, mantle cell lymphoma, elderly, MCLDoorduijn JKKluin-Nelemans HCDove Medical Pressarticletreatmentprogression-free survivalchemotherapymalignant lymphomaMLCGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 1229-1236 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	treatment progression-free survival chemotherapy malignant lymphoma MLC Geriatrics RC952-954.6
spellingShingle	treatment progression-free survival chemotherapy malignant lymphoma MLC Geriatrics RC952-954.6 Doorduijn JK Kluin-Nelemans HC Management of mantle cell lymphoma in the elderly patient
description	Jeanette K Doorduijn,1 Hanneke C Kluin-Nelemans2 1Department of Hematology, Erasmus MC, Rotterdam, The Netherlands; 2Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Abstract: Mantle cell lymphoma is a relatively rare B-cell lymphoma with a specific genetic lesion and a typical immunophenotypic profile. The median age is 65 years. There is no curative treatment, except allogeneic stem cell transplantation for a selected group of patients. For the majority of patients, especially the elderly, the aim of therapy should therefore be a long progression-free survival. Age and comorbidity may hamper the use of the most active treatment regimen, such as high dose cytarabine and autologous stem cell transplantation. Therefore, it is a challenge to select the most appropriate therapy for an elderly patient. Studies specifically designed for elderly patients are rare. A recently performed large randomized study for elderly patients, however, has shown that R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by maintenance rituximab can result in a long progression-free survival. For patients too frail for R-CHOP chemotherapy, a treatment should be offered that benefits the patient in reducing the symptoms of the disease without causing too many side effects. Progression or relapse will occur in all patients sooner or later. Second-line treatment should again be carefully selected. Several options are mentioned. New drugs are being developed, and new combinations are investigated. Further improvement in the outcome of patients with mantle cell lymphoma is expected. Participation in well-designed clinical trials, also by elderly patients, is important to find the real benefit that can be achieved, and to get information on the tolerability of these treatments in this age group. Keywords: treatment, chemotherapy, malignant lymphoma, mantle cell lymphoma, elderly, MCL
format	article
author	Doorduijn JK Kluin-Nelemans HC
author_facet	Doorduijn JK Kluin-Nelemans HC
author_sort	Doorduijn JK
title	Management of mantle cell lymphoma in the elderly patient
title_short	Management of mantle cell lymphoma in the elderly patient
title_full	Management of mantle cell lymphoma in the elderly patient
title_fullStr	Management of mantle cell lymphoma in the elderly patient
title_full_unstemmed	Management of mantle cell lymphoma in the elderly patient
title_sort	management of mantle cell lymphoma in the elderly patient
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/696b190221214942a998d12a967316cc
work_keys_str_mv	AT doorduijnjk managementofmantlecelllymphomaintheelderlypatient AT kluinnelemanshc managementofmantlecelllymphomaintheelderlypatient
_version_	1718400893220552704

Management of mantle cell lymphoma in the elderly patient

Ejemplares similares